{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"24.3","value":"9.1"}]}],"title":"By Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.1","upperLimit":"42.3","value":"24.2"}]}],"title":"By Day 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.8","upperLimit":"66.5","value":"48.5"}]}],"title":"By Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.1","upperLimit":"79.6","value":"63.6"}]}],"title":"By Day 10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.1","upperLimit":"79.6","value":"63.6"}]}],"title":"By Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.3","upperLimit":"84.4","value":"69.7"}]}],"title":"By Day 19"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.3","upperLimit":"84.4","value":"69.7"}]}],"title":"By Day 23"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.3","upperLimit":"84.4","value":"69.7"}]}],"title":"By Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.3","upperLimit":"84.4","value":"69.7"}]}],"title":"By Day 36"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.3","upperLimit":"84.4","value":"69.7"}]}],"title":"By Day 43"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.3","upperLimit":"84.4","value":"69.7"}]}],"title":"By Day 50"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.3","upperLimit":"84.4","value":"69.7"}]}],"title":"By Day 57"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Response is defined as corrected serum calcium (CSC) ≤ 11.5 mg/dL, within 10 days after the first dose of denosumab. For all CSC values, if albumin was \\< 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium \\[mg/dL\\] + (0.8 x (4 - serum albumin \\[g/dL\\]))","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15.","id":"OG000","title":"Denosumab"}],"paramType":"NUMBER","populationDescription":"Response Analysis Subset","reportingStatus":"POSTED","timeFrame":"Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57","title":"Percentage of Participants With a Response by Visit","type":"SECONDARY","unitOfMeasure":"percentage of participants"}